Pulmatrix to Merge With Eos SENOLYTIX, Rebrand on Nasdaq

Pulmatrix ( (PULM) ) has shared an announcement.

On March 26, 2026, Pulmatrix agreed to acquire Eos SENOLYTIX in an all-stock merger that will leave pre-merger Eos investors owning about 94% of the combined company, which will be renamed Eos SENOLYTIX, Inc. and is expected to continue trading on Nasdaq under the ticker EOSX. The deal, unanimously approved by both boards and targeted to close in mid-2026 pending shareholder and regulatory approvals, effectively transforms Pulmatrix into an anti-aging biotech focused on Eos’s AI-driven MitoXcel peptide platform and lead candidate PTC-2105 for sarcopenia and related metabolic disorders.

Concurrent private financings totaling about $19 million, including $1 million of Pulmatrix Series B preferred stock and up to $18 million of Eos bridge and note funding, are structured to support the combined company’s clinical pipeline through key milestones. The transaction strengthens Eos’s capital position and governance control, installs Eos leadership at the helm of the merged entity, and positions the company as a new player in gerotherapeutics competing with and complementing GLP-1-based obesity treatments by focusing on improving body composition and healthspan rather than weight loss alone.

The most recent analyst rating on (PULM) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Pulmatrix stock, see the PULM Stock Forecast page.

Spark’s Take on PULM Stock

According to Spark, TipRanks’ AI Analyst, PULM is a Neutral.

The score is weighed down primarily by very weak financials (near-zero TTM revenue, ongoing losses, and continued cash burn with a shrinking equity base). Technicals add pressure given a clear downtrend versus key moving averages and negative MACD. Valuation offers limited support due to a negative P/E and no dividend, and the terminated reverse-merger introduces additional uncertainty.

To see Spark’s full report on PULM stock, click here.

More about Pulmatrix

Pulmatrix, Inc. is a Nasdaq-listed biotechnology company that has historically focused on developing inhaled therapeutics and is now repositioning itself via acquisition to become a platform for aging-related medicines. Eos SENOLYTIX is a privately held biotechnology firm developing first-in-class gerotherapeutic peptide drugs targeting mitochondrial dysfunction and cellular senescence to treat sarcopenia, obesity and other age-related diseases.

Average Trading Volume: 42,021

Technical Sentiment Signal: Sell

Current Market Cap: $5.51M

For a thorough assessment of PULM stock, go to TipRanks’ Stock Analysis page.